Human Genome Sciences Inc

Human Genome Sciences — Investor Day (April 2011)

59 slides from Human Genome Sciences's investor day presentation, Apr 14, 2011

  1. Slide 1: Analyst and Investor Meeting April 14, 2011

    Analyst AND investor meeting April 14, 2011

  2. Slide 2: David Southwell, Chief Financial Officer

    Analyst and Investor Meeting David Southwell Executive Vice President and Chief Financial Officer April 14, 2011 2

  3. Slide 3: Note Regarding Forward-Looking Statements

    Note Regarding Forward-Looking Statements 3 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome

  4. Slide 4: Today's Agenda

    Strategic Priorities BENLYSTA(r) Commercial Update BENLYSTA Clinical Update Mid/Early Stage Portfolio Financial Wrap Up and General Q & A TODAY'S AGENDA 4

  5. Slide 5: Today's Presenters

    HGS PRESENTERS H. Thomas Watkins President and Chief Executive Officer Barry Labinger Executive Vice President and Chief Commercial Officer David Stump, M.D. Executive Vice President, Research and Development David Southwell Executive Vice President and Chief Financial Officer AVAILABLE FOR QUESTION

  6. Slide 6: H. Thomas Watkins, President and Chief Executive Officer

    Analyst and Investor Meeting H. Thomas Watkins President and Chief Executive Officer 6

  7. Slide 7: Strategic Priority: Successfully launch and commercialize BENLYSTA

    Strategic prioritY 1 Successfully launch and commercialize BENLYSTA(r) 7

  8. Slide 8: Strategic Priority 2: Achieve full potential of BENLYSTA

    Achieve the full therapeutic and commercial potential of BENLYSTA through further development in SLE and other B-cell mediated diseases Strategic prioritY 2 8

  9. Slide 9: Strategic Priority 3: Strengthen the HGS product pipeline

    9 Initiation of Phase 3 trial in Asia planned 2011 Initiation of Phase 3 trial of subcutaneous formulation planned 2011 Sales to Strategic National Stockpile under U.S. Government contract Phase 2 trial planning underway Formerly FP-1039. Rights acquired March 2011 from FivePrime Therapeutics Strate

  10. Slide 10: Barry Labinger, Chief Commercial Officer

    Analyst and Investor Meeting Barry Labinger Executive Vice President and Chief Commercial Officer April 14, 2011 10

  11. Slide 11: BENLYSTA Launch Update

    BENLYSTA Launch update Market Opportunity Access and Reimbursement Marketing Plan Field organization Product positioning Consumer programs Performance Tracking Europe Progress 11

  12. Slide 12: BENLYSTA Initial U.S. Market: 200,000 Patients

    Mild 33% Severe 22% Moderate 45% Initial Target 200,000 1,500,000 Patients with Lupus and Related Conditions* 325,000 SLE Patients Treated by Rheumatologists** * Per Lupus Foundation of America ** Per primary market research BENLYSTA INITIAL U.S. Market: 200,000 Patients 12

  13. Slide 13: Indications and Usage

    Indications and Usage 13 BENLYSTA (belimumab) 10 mg/kg is indicated for the treatment of adult patients with active, autoantibody^positive, systemic lupus erythematosus who are receiving standard therapy. Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe act

  14. Slide 14: Labeled Indication: Treatment of SLE

    Labeled Indication treatment of sle Auto-antibody positive 72% in Phase 2 trial at baseline 100% in medical history Severe active lupus nephritis, severe active CNS lupus Acute manifestations Often requires cyclophosphamide As acute manifestations are treated, many patients continue with chronic act

  15. Slide 15: Use of Rituximab and Cyclophosphamide

    Use of Rituximab and Cyclophosphamide 15 Source: HGS and GSK market research Cyclophosphamide Rituxan Percent of SLE Patients 11% 2% 5% Ever used Currently using 2%

  16. Slide 16: Effect on concomitant steroid treatment

    Effect on concomitant steroid treatment In BLISS-76 and BLISS-52, 46% and 69% of patients, respectively, were receiving prednisone at doses >7.5 mg/day at baseline. The proportion of patients able to reduce their average prednisone dose by at least 25% to ^7.5 mg/day during Weeks 40 through 52 was n

  17. Slide 17: Labeling aligns with study design and clinical data

    Benlysta labeling aligns with study design and clinical data Important clinical endpoints Effect on severe SLE flares The probability of experiencing a severe SLE flare, as defined by a modification of the SELENA-Trial flare criteria which excluded severe flares triggered only by an increase of the

  18. Slide 18: BENLYSTA Safety

    Benlysta safety Warnings and precautions Mortality Serious infections Malignancy Hypersensitivity reactions, including anaphylaxis Infusion reactions Depression Immunization Concomitant use with other biologic therapies or IV cyclophosphamide Most commonly reported adverse reactions: nausea, diarrhe

  19. Slide 19: Rheumatologist awareness and intent to use

    Rheumatologist awareness of benlysta and intent to use 19 100% Source: HGS and GSK market research Awareness Aided Unaided 90% 90% Percent of Rheumatologists Intent to Use

  20. Slide 20: Access & Reimbursement

    ACCESS & REIMBURSEMENT HUMAN GENOME Sciences

  21. Slide 21: BENLYSTA Pricing and Coverage

    BENLYSTA Pricing and Coverage ~$35,000 WAC price for average patient per year Varies by body weight 13 infusions Within range of biologics for other chronic autoimmune diseases Coverage under Medical Benefit Subject to prior authorization Typical for biologics Step therapy expected 21

  22. Slide 22: Reimbursement process

    Appropriate Patient Identified Benefits Verification Prior auth Step therapy (if required) Infusion Claim Submission Reimbursement Reimbursement process hgS and GSK Support Physician and Patient Access Plan specific process Manual process until product-specific reimbursement code Temporary Q-Code gr

  23. Slide 23: BENLYSTA Gateway support

    Provider Patient Live Answer 8am-8pm M-F (ET) 1-877-4-BENLYSTA Benefit Verification & Investigation Financial Assistance Programs Product Support AE Reporting Medical Information Nurse Hotline Benlysta Gateway 23

  24. Slide 24: Payer distribution for SLE

    Payer distribution for sle 24 Note: "Other" = Workers' Compensation, no charge/charity care, blank or unknown Source: Years, 2004 to 2007: National Ambulatory/Medical Care Survey / National Hospital Ambulatory Medical Care Survey, survey conducted by the National Center for Health Statistics Self-Pa

  25. Slide 25: Estimate of Out of Pocket Drug Costs

    Estimate of Out of Pocket DRUG Costs Commercially insured 25 (CHART) No OOP Cost Fixed copay ($50-100) Coinsurance (10-20%) with cap (up to $2500) Coinsurance (10-20%), no cap

  26. Slide 26: BENLYSTA Financial Assistance Programs

    BENLYSTA Financial Assistance Programs 26 Patient Assistance Program Free drug Uninsured ^ 500% Federal Poverty Level Copay Assistance Commercially insured ^ 500% FPL Full copay/co-ins $7,000 annual max Site of care payment >500%- ^ 750% FPL 50% copay/co-ins $3,500 annual max Reimbursed

  27. Slide 27: BENLYSTA Marketing Plan

    BENLYSTA MARKETING PLAN HUMAN GENOME Sciences

  28. Slide 28: Field Implementation

    Field Implementation 28 SLE Experts Academic and Large Community Hospitals (465 accounts) Top Community Rheum Infusion Centers (200 Clinics) Other Community Rheum Accounts (1600 clinics) Commercial & Government Payers 18 Medical Science Liaisons (HGS) 69 Account Managers (HGS) 78 Account Managers (G

  29. Slide 29: HGS Sales Force

    Selected from ~5,000 applicants Top performers, best fit Average Industry experience 10+ years 98% biologic experience 77% rheumatology experience 84% buy-and-bill / infused biologic experience HGS Sales Force Out in the field since march 24 29

  30. Slide 30: BENLYSTA positioning in SLE treatment algorithm

    Benlysta positioning in SLE treatment algorithm Initial Therapies (persistent symptoms) Low dose corticosteroids Anti-malarials 30 Acute (severe active)1 Chronic Intensified Therapy (persistent symptoms) High dose corticosteroids Immunosuppressants Methotrexate Mycophenolate mofetil Azathioprine Cyc

  31. Slide 31: Educated lupus patients more likely to request new therapies

    educated Lupus Patients are more likely to request new therapies 31

  32. Slide 32: Performance Tracking

    Performance Tracking key metrics for initial uptake (Available Beginning 2Q11 Conf Call) 32 Account ordering trends By segment (acad ctrs, comm clinics, inf ctrs) Self reported trial Primary market research Benefit verifications in BENLYSTA Gateway Trends over time No absolute numbers # plans reimbu

  33. Slide 33: Europe Update

    Europe Update 33 Marketing Authorization Application review ongoing EMA decision expected 2H 2011 CHMP opinion expected by mid-year Many markets require 9-12 months for pricing/reimbursement HGS senior team in place Headquarters near Geneva, Switzerland Close collaboration with GSK regional leadersh

  34. Slide 34: BENLYSTA Launch Summary

    Benlysta Launch Summary 34 Large market opportunity and favorable label U.S. launch off to a good start Positive reception from rheumatologists/staff Outstanding team in place and well prepared Launch preparations in Europe on track

  35. Slide 35: Questions

    QUESTIONS HUMAN GENOME Sciences

  36. Slide 36: David Stump, Research and Development

    Analyst and Investor Meeting David Stump, M.D. Executive Vice President, Research and Development April 14, 2011 36

  37. Slide 37: BENLYSTA life cycle plan progressing

    BENLYSTA life cycle plan progressing Post-marketing studies Long term continuation trials Subcutaneous formulation New indications Advance mid-stage development and expand early-stage pipeline Mapatumumab HGS1029 HGS10361, fibroblast growth factor ligand trap Research & Development priorities 37 1Fo

  38. Slide 38: Post-Marketing Studies

    Post-Marketing Studies Long-term safety trial (N=~5,000 patients) 5 year treatment Assessment of events of interest Serious and opportunistic infections, malignancies, mortality, depression/suicidality Patients of black race Efficacy and safety in randomized, controlled trial Lupus nephritis Efficac

  39. Slide 39: Post-Marketing Studies Continued

    Post-Marketing Studies Continued Pediatric assessment ~100 patients, age 5-17, active SLE Safety, efficacy, pharmacokinetics Assess response to certain vaccines Randomized clinical trial No REMS required-med guide only Pregnancy registry open by the end of 2011 Plan to start post-marketing studies 2

  40. Slide 40: Continuing to build safety database

    CONTINUING TO BUILD SAFETY DATABASE Approximately 1,000 PATIENTS IN ONGOING CONTINUATION TRIALS Phase 2 200 patients on treatment after 6 years (as of July 2010) Out of 449 originally treated Continue 10 years or until <100 patients Phase 3, U.S. Continue 5 years or until <100 patients Phase 3, ex-U

  41. Slide 41: BENLYSTA Subcutaneous Formulation

    41 New formulation potentially allows for 1x per week dosing May improve convenience for some patients Phase 1 bioavailability study currently evaluating higher concentration in new formulation Goal is weekly administration while maintaining exposure similar to 10mg/kg IV dose Phase 3, placebo-contr

  42. Slide 42: Potential Opportunities in Additional B-Cell Mediated Diseases

    Potential Opportunities in Additional B-CELL Mediated Diseases Proof of concept/exploratory studies Sjogren's Syndrome1 Waldenstrom's Disease1 Transplant1 Idiopathic thrombocytopenic purpura Myasthenia gravis Idiopathic membranous nephropathy Phase 2 vasculitis trial planning underway Regulatory dis

  43. Slide 43: Rationale for BLyS Antagonists in Autoimmune Diseases

    Rationale for BLyS Antagonists in Autoimmune Diseases BLyS is overexpressed in patients with SLE and other autoimmune diseases1 Elevated levels of BLyS correlate with disease activity2 Worsening disease activity (using SELENA SLEDAI) was predicted by rises in serum BLyS concentrations Autoantibodies

  44. Slide 44: ANCA-Associated Vasculitis: Rationale for Potential Efficacy

    ANCA-ASSOCIATED VASCULITIS RATIONALe FOR POTENTIAL EFFICACY OF BENLYSTA Activity on biomarkers Normalization of anti-dsDNA antibodies Reduction in immunoglobulins Increased complement (C3 and C4) levels Lymphocyte effects Reduced activated B cells and short-lived plasma cells Vascular system organ i

  45. Slide 45: SLE Vasculitis Response to Belimumab

    45 SLE Vasculitis Response to Belimumab (SELENA SLEDAI)

  46. Slide 46: ANCA-Associated Vasculitis Phase 2 Planned

    ANCA-ASSOCIATED VASCULITIS PHASE 2 PLANNED Autoimmune condition that involves inflammation in the blood vessels Autoantibodies Inflammation-increased immunoglobulins, low complement, elevated CRP Lymphocytic infiltration of the blood vessel-increased giant cells, plasma cells and T-cells Blood vesse

  47. Slide 47: TRAIL Pathway Offers Therapeutic Opportunities Across Cancers

    TRAIL Pathway Offers Therapeutic Opportunities Across a Broad Range of Cancers 47 Mapatumumab (HGS-ETR1) Targets TRAIL apoptosis pathway Proof of concept randomized Phase 2 chemotherapy combo trial underway in hepatocellular carcinoma HGS1029 (IAP inhibitor) Novel intracellular target in apoptosis p

  48. Slide 48: HGS10361 Affects FGF Ligand-Dependent Signaling Pathways

    HGS10361 Affects Multiple, Pathogenic FGF Ligand-Dependent Signaling Pathways in Cancer Cells 48 Potentially impacted by HGS1036 Modified from Nature Reviews | Cancer Volume 10 | February 2010 | 123 1Formerly FP-1039; in-licensed from FivePrime Therapeutics

  49. Slide 49: 2011 R&D Development Milestones

    2011 R&D DEVELOPMENT MILESTONES Finalize protocols and reach regulatory agreement on BENLYSTA post-marketing studies Initiate Phase 3 BENLYSTA sub-Q formulation study Complete regulatory discussions and begin site initiation activities for vasculitis Phase 2 study Continue exploratory work in additi

  50. Slide 50: Questions

    QUESTIONS HUMAN GENOME Sciences

  51. Slide 51: David Southwell, Chief Financial Officer

    Analyst and Investor Meeting David Southwell Executive Vice President and Chief Financial Officer April 14, 2011 51

  52. Slide 52: Select financial data and 2011 guidance

    Cash and investments at December 31, 2010: $933 million Expected cash and investments at year-end 2011: $550-$650 million Includes in-licensing of HGS10361 Expect SG&A and R&D expense to total $330-$390 million SG&A expense increase to $150-$170 million primarily reflects full-year impact of U.S. ex

  53. Slide 53: U.S. Revenue Recognition

    Drop-ship direct to customer U.S. Revenue Recognition At Launch Sell-Through Basis 53 2011 Revenue Recognition 2011 Revenue Recognition Drop-ship direct to customer HGS Fill/Finish GSK Distribution Centers Specialty Distributor Wholesaler Physician Hospital

  54. Slide 54: Commercial collaboration accounting: U.S. BENLYSTA sales

    Commercial collaboration accounting U.S. BENLYSTA SALES 54 Total U.S. BENLYSTA Product P&L Total U.S. BENLYSTA Product P&L Net Product Sales A Cost of Product Sales B Gross Profit C SG&A Expense D R&D Expense1 (global) E Operating Profit OP 100% Impact on HGS P&L Impact on HGS P&L A Net Product Sale

  55. Slide 55: Commercial collaboration accounting: International BENLYSTA sales

    Commercial collaboration accounting International BENLYSTA SALES 55 1If income: separate line item in revenue section of P&L-Commercial Collaboration Income. If expense: HGS' share of split will be in Commercial Collaboration Expense line above Operating Income on P&L. Intl BENLYSTA Product P&L Intl

  56. Slide 56: Spending focused on maximizing the BENLYSTA opportunity

    Spending going forward is focused on maximizing the BENLYSTA opportunity Accounting for BENLYSTA reflects the 50/50 partnership with GSK Drive Commercial Success Maximize Opportunity in BENLYSTA WELL-CAPITALIZED to Fuel Worldwide LAUNCH OF BENLYSTA Advance New Pipeline Products 56 Drive Profitabilit

  57. Slide 57: Wrap Up and General Q&A

    H. Thomas Watkins President and Chief Executive Officer Wrap Up and General Q&A

  58. Slide 58: Well-positioned to generate significant value

    WELL-POSITIONED TO GENERATE SIGNIFICANT VALUE We are focused on maximizing the BENLYSTA franchise We are well capitalized to fund the BENLYSTA launch We expect to reach profitability in 2013 58

  59. Slide 59: Building Shareholder Value

    Potential Blockbuster Product Pipeline to Fuel Future Growth Manufacturing Excellence Commercial Readiness World-Class Partner Seasoned Leadership A Formula for Sustainable Growth 59 Building Shareholder Value

Human Genome Sciences — Investor Day (April 2011) on 6ix